


Cite this: *RSC Adv.*, 2020, 10, 15148

Received 11th February 2020

Accepted 31st March 2020

DOI: 10.1039/d0ra02850a

rsc.li/rsc-advances

Investigating partitioning of free *versus* macrocycle bound guest into a model POPC lipid bilayer†

Harshita Kumari,^{ID}*^a Andrew Eisenhart,^b Jinnipha Pajoubpong,^a Frank Heinrich*^{c,d} and Thomas L. Beck*^b

We report on the permeation of free and macrocycle-bound avobenzone across a POPC lipid bilayer through combined neutron reflectometry experiments and molecular dynamics simulations. Results indicate that the *p*-phosphonated calix[8]arene macrocycle limits the avobenzone penetration into the upper leaflet of the membrane. Hence, it could serve as a useful vehicle for safer formulations.

Introduction

Supramolecular chemistry is transitioning from synthesizing unusable host–guest complexes to designing and developing molecular machines.^{1–3} Stoddart used molecules on the nanometric scale as switches in electronic devices and linear motor-molecules in nanoelectromechanical systems.^{4,5} Investigating molecular movements and controlling them will define the next decade of supramolecular chemistry. This new approach has motivated us to investigate the mechanism of penetration of a novel supramolecular host–guest complex across lipid bilayers/biomembranes, which is potentially useful to control UV radiation exposure, a potent cause of skin cancer.

The prevalence of malignant melanoma (a type of skin cancer), despite the extensive use of sunscreens, is a global concern.^{6,7} UVA and UVB penetration across the epidermis leads to generation of reactive oxidative species, DNA/protein/lipid damage and activation of varying signal transduction pathways that compromises the skin's defence systems.^{8,9} The use of sunscreens is continuously on the rise; however, the toxic effect of some organic sunscreens^{10,11} on coral reefs^{12–14} and challenges with formulation of inorganic sunscreen agents, such as, zinc oxide and titanium dioxide,^{15–17} has limited the number of available molecules that provide effective UV protection.

The photo-stability of sunscreen actives, toxicological impacts of photo-degradation products and controlling skin penetration are three of the major challenges in this area.

Sunscreens, such as, oxybenzone/benzophenone-3 are emerging as environmental and human contaminants as they have been detected in human urine (97% of the population) or impacting coral reefs.¹⁸ Thus, skin penetration across deeper layers (dermis) is a major concern with organic photoactives. Although macromolecular quantitative estimation of skin penetration of sunscreen is possible *via* radiolabelled ¹⁴C tape stripping assays on human/pig skin,¹⁹ a nanometric molecular-level understanding is still lacking. In this work, we study the interaction of an organic active (avobenzone, Fig. 1) with model lipid bilayer membranes, and we examine how complexing it with a macrocycle could potentially impact/restrain its pathway across the bilayer membrane.

For this study, we chose *p*-phosphonated calix[8]arene (calix [8]-PO₃H₂)²⁰ as the host molecule and avobenzone as the sunscreen agent (Fig. 1). Calixarenes are cyclic oligomers of several phenolic units connected with methylene bridges.^{21–24} Although sparingly soluble in water, the base molecule has been modified with functional groups, such as, phosphonate, sulphonate or amine to induce aqueous solubility. In addition, the cavity size can be modulated to accommodate a suitably sized guest. Our recent rat and human cell toxicology study on calix[8]-PO₃H₂ revealed its non-toxic behaviour that renders it as a useful biomedical macrocycle for potential application as a nanocarrier.²⁵ Complexation of calix[8]-PO₃H₂ with

^aJames L. Winkle College of Pharmacy, University of Cincinnati, 231 Albert Sabin Way, MSB #3109 C, Cincinnati, OH 45267-0514, USA. E-mail: kumariha@ucmail.uc.edu

^bDepartment of Chemistry, University of Cincinnati, Cincinnati, Ohio 45221, USA. E-mail: becktl@ucmail.uc.edu

^cDepartment of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania, 15213, USA. E-mail: fheinrich@cmu.edu

^dCenter for Neutron Research, National Institute of Standards and Technology, Gaithersburg, Maryland, 20988, USA

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra02850a




Fig. 1 Chemical structure of avobenzone and *p*-phosphonated calix [8]arene.



avobenzone²⁶ was chosen for three reasons: (a) water solubility of the macrocycle; (b) large internal cavity and upper rim H-bonding functionality of the host and (c) non-toxic behaviour towards rat and human cell lines.²⁵

Avobenzone (1-(4-methoxyphenyl)-3-(4-tertbutylphenyl)propane-1,3-dione) also known as Parsol 1789 is a broad-spectrum sunscreen agent. Its ability to absorb both UVA and UVB radiations makes it one of the most useful sunscreen agents that prevents photodamage of skin. However, once exposed to sun, avobenzone offers only 30 minutes of photoprotection. Hence, it is formulated with photostabilizers, such as octocrylene, which is a known endocrine disrupter and releases free radicals.^{27–29} Experimental and theoretical studies suggest that the chelated enol form is the ground state. Upon UV irradiation in polar nonprotic solvents, the enol form converts to the keto tautomer.³⁰ Herein, we are exploring a rather inert macrocycle that could provide a confined environment for photostability and/or controlled penetration across bilayer. In this study, we have limited our scope to the interaction of free *versus* macrocycle-complexed avobenzone with an artificial bilayer.

Neutron reflectometry

We tested the interaction of avobenzone and calix[8]-PO₃H₂ with single-membrane POPC (1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine) tethered lipid bilayer membranes (tBLMs).³¹ Solvent-immersed tBLMs allow for a characterization of the membrane before and after addition of avobenzone and calix[8]-PO₃H₂ from solution, thus mimicking the encounter of those substances by the membrane in the body. This differentiates tBLMs from conventionally used stacked lipid bilayer model systems^{32,33} in air. The chemical structure of the glycerophospholipid POPC consists of a zwitterionic phosphatidylcholine headgroup linked to a glycerol, which is ester-bound to two fatty acid groups – palmitic acid (C16:0) and oleic acid (C18:1). This fatty acid composition mimics that of phospholipids mainly found in the eukaryotic cell membrane,³⁴ including keratinocytes.³⁵ In addition to phospholipids, native eukaryotic membranes also contain glycolipids, sterols and various proteins, which are not included in the current simplified model system.

Using a POPC model membrane constitutes the first step in establishing more complex SC lipid membrane model systems. Specifically, in the cornification process, keratinocytes, which are living cells containing phospholipid bilayer membranes, a nucleus and cytoplasm, are transformed to corneocytes *via* apoptosis. Consequently, the digestion of the nucleus and the loss of the cytoplasm and all intracellular organelles occur, whereas the cell membrane is replaced by the cornified cell envelope (CE). The CE consists of crosslinked structural proteins (*e.g.* loricerin, involucrin), which are also covalently linked to ceramides on the exterior surface providing a hydrophobic interface between the CE and the intercellular lipid lamellae.^{36,37}

The simplified biomimetic lipid bilayer model has allowed us to investigate its fundamental interaction with molecules of interest between the molecular and the micrometre scale using neutron reflectometry (NR). Because neutrons are uncharged

and highly penetrating particles that have wavelengths comparable to molecular sizes and inter-molecular distances, neutrons are an ideal probe for characterizing the structure and dynamics of complex materials such as lipid bilayers. Moreover, neutrons interact with hydrogen and deuterium differently allowing one to use of the scattering contrast between H₂O and D₂O to investigate hydrogen-rich biological membranes.³⁸ There are three different neutron scattering techniques commonly applied for different membrane models: (a) neutron diffraction for stacked bilayers (b) small angle neutron scattering for vesicles and bicelles, and (c) NR for single bilayers such as the POPC used in this work.^{38,39}

NR is a flexible tool in structural biology due to its ability to discern the biomolecular architectures of lipid membranes and membrane-associated proteins without destroying the sample. It allows to mimic biological processes and to measure their structural responses. However, it does require specific deuteration to resolve individual components of interest. For this study, we conducted NR experiments with hydrogenated and deuterated POPC bilayers, and simultaneously analysed both data sets to obtain one structural model.

NR measurements were performed at the CGD-Magik reflectometer⁴⁰ at the NIST Center for Neutron Research (NCNR). Reflectivity curves were recorded for momentum transfer values $0.01 \leq q_z \leq 0.25 \text{ \AA}^{-1}$. For each measurement, adequate counting statistics were obtained after 5–7 h. The NCNR fluids cell⁴¹ allows for *in situ* solvent exchange; therefore, subsequent measurements were performed on the same sample area. The entire flow cell was maintained at room temperature (RT). Solvent exchange was accomplished by rinsing ~10 ml of water through the cell (volume ~1.3 ml) using a syringe.

We conducted a set of NR experiments with a hydrogenated POPC bilayer and another identical set of experiments with a deuterated POPC-d₃₁ bilayer. After measurement of the as-prepared bilayer in H₂O and D₂O, avobenzone was added to the sample cell at a concentration of 100 μM dissolved in H₂O and D₂O. NR measurements were conducted while the bilayer was in contact with either solution. The sample was measured again after rinsing with H₂O and D₂O, respectively. Data for both bilayers were co-refined sharing conserved model parameters across data sets, in particular those associated with the volume profile of avobenzone. The co-refinement of data from two lipid bilayers with differently labelled hydrocarbon chains significantly boosted the resolution of the avobenzone profile, in this region. We performed an identical set of measurements with a 100 μM complex of 1 : 1 avobenzone : calix[8]-PO₃H₂ instead of pure avobenzone.

1D-component volume occupancy (CVO) profiles along the lipid bilayer normal were obtained as previously described.^{42–44} Bilayer fit parameters were the hydrocarbon thickness for each bilayer subsection, the bilayer completeness, and the thickness of the sub-membrane space. One roughness parameter was applied to all distributions. The thin layer of native silicon oxide was modelled by a single distribution with individual roughness and thickness parameters. Hermite splines defined by control points that were on average 15 \AA apart were used to model the CVO profiles of avobenzone and calix[8]-PO₃H₂. The number of



control points was iteratively refined during model optimization for each CVO profile. Fit parameters associated with each control point were a volume occupancy, a deviation from equidistant separation, and (for the CVO profile of the complex) a nSLD (neutron scattering length density) value between those of avobenzone and calix[8]-PO₃H₂. Such a variable nSLD per control point allowed us to separate individual CVO profiles for avobenzone (average nSLD $\rho = 1.37 \times 10^{-6} \text{ \AA}^{-2}$) and calix[8]-PO₃H₂ ($\rho = 2.73 \times 10^{-6} \text{ \AA}^{-2}$). The exchange of labile protons in isotopically different buffers affects the nSLD of molecular components and was taken into account during data analysis. Optimization of model parameters was performed using the *ga_refl* and *Refl1D* software packages developed at the NCNR.⁴⁵ A Monte Carlo Markov chain-based global optimizer⁴⁵ was used to determine fit parameter confidence limits.

Results for NR measurements with avobenzone without calix [8] are shown in Fig. 2A and B and Table S1.[†] The substrate-supported POPC and POPC-d₃₁ lipid bilayers were complete (surface coverage 1.00 ± 0.01) and had total hydrocarbon thicknesses of $30 \pm 1 \text{ \AA}$, which is $\sim 3 \text{ \AA}$ larger than those determined for stacked lipid bilayer membranes and vesicles.⁴⁶ Avobenzone is observed interacting with the lipid bilayer at the hydrocarbon/headgroup interface of the substrate-distal lipid leaflet or solvent-side region without penetrating the bilayer to the substrate-proximal leaflet. The observed surface volume density of avobenzone is $3.0 \pm 0.5 \text{ \AA}^3/\text{\AA}^2$ during bilayer incubation and $3.8 \pm 0.4 \text{ \AA}^3/\text{\AA}^2$ after solvent rinse, showing a stable bilayer-association with 1 avobenzone molecule per ~ 2.7 lipid molecules. Adding avobenzone does not affect the structural integrity of the lipid bilayer as the bilayer completeness remains at $100 \pm 1\%$. A substantial thickening of the lipid bilayer of $\sim 0.5 \text{ \AA}$ per leaflet upon avobenzone addition is observed.

Fig. 2C, D and Table S2[†] show NR results for the measurements involving the avobenzone : calix[8]-PO₃H₂ complex. The POPC and POPC-d₃₁ lipid bilayers were structurally identical to those prepared for the avobenzone measurements, albeit the hydrocarbon region was on average 2 \AA thinner, and therefore closer to literature values.⁴⁶ While a comparable surface volume density of bilayer-associated avobenzone of $2.3 \pm 0.6 \text{ \AA}^3/\text{\AA}^2$ (1 avobenzone per ~ 3.1 lipid molecules) was observed, the density of calix[8]-PO₃H₂ arene was barely significant with $0.7 \pm 0.6 \text{ \AA}^3/\text{\AA}^2$. Since the solvent-excluded volume of avobenzone is roughly a third of that of calix[8]-PO₃H₂, the molar ratio of calix[8]-PO₃H₂ to avobenzone at the membrane is substantially less than 1. This indicates a dissociation of avobenzone from calix [8]-PO₃H₂ before or upon bilayer interaction, which is consistent with the -weak hydrogen bonding of avobenzone to calix[8]-PO₃H₂ at the upper rim.²⁶ Post-rinsing, both the amount of bilayer-associated avobenzone and macrocycle remains unchanged. The lipid bilayer remains structurally intact throughout the experiment.

Molecular dynamics simulations

Molecular dynamics simulations were conducted using the GROMACS/4.2.1 suite of programs. The system was set up by conjoining an equilibrated box containing a POPC lipid bilayer




Fig. 2 NR-derived CVO profiles of a hydrogenated POPC bilayer (A) while incubating $100 \mu\text{M}$ avobenzone and (B) post-rinse; and a second hydrogenated POPC bilayer (C) while incubating $100 \mu\text{M}$ avobenzone and calix[8]-PO₃H₂ and (D) post-rinse. 68% confidence limits are shown for avobenzone and calix[8]-PO₃H₂ profiles. A complementary set of POPC-d₃₁ bilayers were identically prepared and measured, and simultaneously analysed with the respective data sets collected on the hydrogenated POPC bilayers (data not shown).

with two equilibrated water boxes. The combined configuration forms a rectangular prism of dimensions $6 \text{ nm} \times 6 \text{ nm} \times 12 \text{ nm}$. Forcefields used were CHARMM27 for the lipids, the TIP3P water model, and the CHARMM general forcefield for avobenzone and calix[8]-PO₃H₂. Initial positions for the



avobenzene molecule and the avobenzene : calix[8]-PO₃H₂ complex were chosen to be 2 nm from the lipid surface, to prevent premature interaction with the POPC surface. The initial configuration of the avobenzene : calix[8]-PO₃H₂ complex was chosen following an unrestrained MD equilibration of the two species in an aqueous environment, this resulting structure represents a low energy configuration of the two molecules interacting in a “bowl-solute” conformation. The systems were equilibrated using the NVT ensemble followed by the NPT ensemble for 1 ns and 5 ns, respectively, using the Nose–Hoover thermostat and the Parrinello–Rahman barostat. After equilibration, umbrella pulling simulations were conducted in the negative z-direction to generate configuration windows for the potential-of-mean-force (PMF) calculations. 300 configurations were extracted from the pull trajectories to ensure proper sampling. Each simulation window was re-equilibrated for a short period 0.5 ns, then production runs were conducted. During production, the center of mass of the “pulled” molecule(s) (avobenzene or avobenzene–calix[8]-PO₃H₂) are restrained, but rotation around their centre of mass and molecule flexing is allowed to prevent unrealistic configurations. Each production run was sampled for 6 ns with a 2 fs timestep and coupling times of 2 and 4 fs for the thermostat and barostat respectively. Samples from each production window were analysed using the GROMACS implementation of the weighted histogram analysis (gmx WHAM).⁴⁷ The PMFs were shifted so that zero energy corresponds to the solutes in bulk water.

Fig. 3 (top) shows the free energy change as a function of the distance of avobenzene from the POPC lipid bilayer's centre of mass. A negative change in free energy is observed as avobenzene partitions into the lipid bilayer. The local minimum of the free energy profile is located at ~ 0.7 nm, which indicates that avobenzene after partitioning into the membrane will settle near this position and which is in agreement with the peak of the CVO profiles of avobenzene obtained from the NR experiments (Fig. 2; Tables S1 and S2†).

Fig. 3 (bottom) shows the free energy change as the avobenzene : calix[8]-PO₃H₂ complex approaches the bilayer. In contrast to the result with avobenzene only, a shallow local minimum is located at the surface of the bilayer (3 nm from the bilayer center). Moving into membrane the free energy rises sharply not exhibiting an energetically favourable configuration. This indicates the difficulty the avobenzene : calix[8] complex faces attempting to permeate even the outer layers of the bilayer. The free energy continues to rise after crossing the center of mass of the POPC lipid bilayer further indicating that the forced permeation in our simulations is disrupting the bilayer structure. Error bars in Fig. 3 are omitted for clarity, but standard deviation of each point on the curve is estimated to be between 0.3 and 0.5 kcal mol^{−1} using the bootstrap analysis method.⁴⁷ The local free energy minimum of -1.5 kcal mol^{−1} is too shallow to stably bind a significant amount of the complex at a solution concentration of 100 μ M.⁴⁸ Simulations therefore agree with the absence of a significant amount of calix[8]-PO₃H₂ detected in NR.




Fig. 3 (Top) Schematic showing POPC bilayer and avobenzene. (Bottom) Calix[8]-PO₃H₂ + avobenzene with POPC bilayer.

Conclusions

Combined NR and simulation results from the present study reveal the interaction of avobenzene with the bulk solvent-side region (outer leaflet) of a POPC membrane. Un-complexed avobenzene is shown to strongly penetrate into the membrane and associate with 5 lipid molecules; however, in the presence of calix[8]-PO₃H₂ the complex encounters a large free energy barrier to membrane entry. These energetically favourable positions lead to the penetration of a single avobenzene to the first hydrophobic region of the POPC lipid bilayer, while the avobenzene : calix[8]-PO₃H₂ complex instead enjoys an energetically favourable position at the surface of the bilayer. These preferred positions agree with the NR results showing calix[8]-PO₃H₂ accumulating at the lipid bilayer surface and avobenzene settling in the first hydrophobic region. The avobenzene by itself displays a 2.1 kcal mol^{−1} energy well in the first inner leaflet, higher than the energy well of the avobenzene : calix[8]-PO₃H₂ complex at the lipid bilayer surface (1.2 kcal mol^{−1}). In addition, simulations have identified a free energy minimum for membrane-bound avobenzene 6 Å from the membrane centre, inside the first hydrophobic region of the bilayer. This is in agreement with the experimentally determined peak positions of the avobenzene CVO profiles of 10 ± 3 Å and 7 ± 3 Å (Table S1†). The free energy difference between

membrane bound avobenzone and avobenzone at infinite dilution of $-16 \text{ kcal mol}^{-1}$ estimates to an affinity in the nM range.⁴⁸ This calculated value being lower than the experimental concentration of $100 \text{ }\mu\text{M}$ may suggest that the overall free energy difference between bound and solvated states should be smaller than the calculated $-16 \text{ kcal mol}^{-1}$ if the concentration in the simulated bulk phase matched that of the experiments. These results showcase the ability of the calix[8]- PO_3H_2 macrocycle to reduce the penetration of the avobenzone into a simple lipid bilayer, providing a useful way of anchoring targeted molecules to the surface of a membrane and reducing molecular permeation.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This research is funded by Start-up funds (HK) and NSF grants CHE-1565632 and CHE-1955161 (TLB). FH acknowledges support from the U.S. Department of Commerce through an MSE grant (70NANB17H299). Certain commercial materials, equipment, and instruments are identified in this work to describe the experimental procedure as completely as possible. In no case does such an identification imply a recommendation or endorsement by NIST, nor does it imply that the materials, equipment, or instrument identified are necessarily the best available for the purpose.

Notes and references

- 1 V. Balzani, A. Credi, F. M. Raymo and J. F. Stoddart, *Angew. Chem.*, 2000, **39**, 3348–3391.
- 2 H. Huang, T. Orlova, B. Matt and N. Katsonis, *Macromol. Rapid Commun.*, 2018, **39**, 1700387.
- 3 D. Zhang, A. Martinez and J.-P. Dutasta, *Chem. Rev.*, 2017, **117**, 4900–4942.
- 4 P. M. Mendes, A. H. Flood and J. F. Stoddart, *Appl. Phys. A: Mater. Sci. Process.*, 2005, **80**, 1197–1209.
- 5 R. A. Bissell, E. Córdova, A. E. Kaifer and J. F. Stoddart, *Nature*, 1994, **369**, 133–137.
- 6 B. Kütting and H. Drexler, *Int. Arch. Occup. Environ. Health*, 2010, **83**, 843–854.
- 7 T. S. Poon, R. S. Barnetson and G. M. Halliday, *J. Invest. Dermatol.*, 2003, **121**, 184–190.
- 8 F. H. M. de Melo, F. Molognoni and M. Galvonas, in *Recent Advances in the Biology, Therapy and Management of Melanoma*, 2013, ch. 5, DOI: 10.5772/54937.
- 9 J. A. Ruszkiewicz, A. Pinkas, B. Ferrer, T. V. Peres, A. Tsatsakis and M. Aschner, *Toxicol. Rep.*, 2017, **4**, 245–259.
- 10 M. S. Díaz-Cruz and D. Barceló, *TrAC, Trends Anal. Chem.*, 2009, **28**, 708–717.
- 11 S. Kim and K. Choi, *Environ. Int.*, 2014, **70**, 143–157.
- 12 R. Danovaro, L. Bongiorno, C. Corinaldesi, D. Giovannelli, E. Damiani, P. Astolfi, L. Greci and A. Pusceddu, *Environ. Health Perspect.*, 2008, **116**, 441–447.
- 13 S. L. Schneider and H. W. Lim, *J. Am. Acad. Dermatol.*, 2019, **80**, 266–271.
- 14 M. M. P. Tsui, J. C. W. Lam, T. Y. Ng, P. O. Ang, M. B. Murphy and P. K. S. Lam, *Environ. Sci. Technol.*, 2017, **51**, 4182–4190.
- 15 C. Botta, J. Labille, M. Auffan, D. Borschneck, H. Miche, M. Cabié, A. Masion, J. Rose and J.-Y. Bottero, *Environ. Pollut.*, 2011, **159**, 1543–1550.
- 16 K. Schilling, B. Bradford, D. Castelli, E. Dufour, J. F. Nash, W. Pape, S. Schulte, I. Tooley, J. van den Bosch and F. Schellauf, *Photochem. Photobiol. Sci.*, 2010, **9**, 495–509.
- 17 R. Dunford, A. Salinaro, L. Cai, N. Serpone, S. Horikoshi, H. Hidaka and J. Knowland, *FEBS Lett.*, 1997, **418**, 87–90.
- 18 J. C. DiNardo and C. A. Downs, *J. Cosmet. Dermatol.*, 2018, **17**, 15–19.
- 19 C. Jacques-Jamin, H. Duplan, H. Rothe, O. Vaillant, J. Eilstein, S. Grégoire, R. Cubberley, D. Lange, C. Ellison, M. Klaric, N. Hewitt and A. Schepky, *Skin Pharmacol. Physiol.*, 2017, **30**, 234–245.
- 20 A. D. Martin and C. L. Raston, *Chem. Commun.*, 2011, **47**, 9764–9772.
- 21 K. D. Shimizu and J. Rebek, Jr., *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 12403–12407.
- 22 R. H. Vreekamp, J. P. M. van Duynhoven, M. Hubert, W. Verboom and D. N. Reinhoudt, *Angew. Chem., Int. Ed.*, 1996, **35**, 1215–1218.
- 23 Z. Zhang, A. Drapailo, Y. Matvieiev, L. Wojtas and M. J. Zaworotko, *Chem. Commun.*, 2013, **49**, 8353.
- 24 Y. Zhou, C. Liu, H. Xu, H. Yu, Q. Lu and L. Wang, *Spectrochim. Acta, Part A*, 2007, **66**, 919–923.
- 25 A. Dawn, X. Yao, Y. Yu, J. Jiang and H. Kumari, *Supramol. Chem.*, 2019, **31**, 425–431.
- 26 A. Das, M. Mirzamani, H. Kumari and A. Gudmundsdottir, 2020, manuscript in preparation.
- 27 C. M. Kawakami and L. R. Gaspar, *J. Photochem. Photobiol., B*, 2015, **151**, 239–247.
- 28 J. Wang, L. Pan, S. Wu, L. Lu, Y. Xu, Y. Zhu, M. Guo and S. Zhuang, *Int. J. Environ. Res. Public Health*, 2016, **13**, 782.
- 29 M. Lodén, H. Beitner, H. Gonzalez, D. W. Edström, U. Åkerström, J. Austad, I. Buraczewska-Norin, M. Matsson and H. C. Wulf, *Br. J. Dermatol.*, 2011, **165**, 255–262.
- 30 G. J. Mturi and B. S. Martincigh, *J. Photochem. Photobiol., A*, 2008, **200**, 410–420.
- 31 R. Budvytyte, G. Valincius, G. Niaura, V. Voiciuk, M. Mickevicius, H. Chapman, H.-Z. Goh, P. Shekhar, F. Heinrich, S. Shenoy, M. Lösche and D. J. Vanderah, *Langmuir*, 2013, **29**, 8645–8656.
- 32 G. S. Gooris, M. Kamran, A. Kros, D. J. Moore and J. A. Bouwstra, *Biochim. Biophys. Acta, Biomembr.*, 2018, **1860**, 1272–1281.
- 33 D. Groen, F. Berthaud, J. A. Bouwstra, C. Chapuis, G. S. Gooris and M. Boncheva, *Biochim. Biophys. Acta, Biomembr.*, 2014, **1838**, 310–318.
- 34 N. R. Yepuri, T. A. Darwish, A. M. Krause-Heuer, A. E. Leung, R. Delhom, H. P. Wacklin and P. J. Holden, *ChemPlusChem*, 2016, **81**, 315–321.
- 35 A. Kalinin, L. N. Marekov and P. M. Steinert, *J. Cell Sci.*, 2001, **114**, 3069–3070.



- 36 C. R. Harding, *Dermatol. Ther.*, 2004, **17**, 6–15.
- 37 E. Candi, R. Schmidt and G. Melino, *Nat. Rev. Mol. Cell Biol.*, 2005, **6**, 328–340.
- 38 G. Fragneto, *Eur. Phys. J. Spec. Top.*, 2012, **213**, 327–342.
- 39 G. Fragneto, R. Delhom, L. Joly and E. Scoppola, *Curr. Opin. Colloid Interface Sci.*, 2018, **38**, 108–121.
- 40 J. A. Dura, D. J. Pierce, C. F. Majkrzak, N. C. Maliszewskyj, D. J. McGillivray, M. Lösche, K. V. O'Donovan, M. Mihailescu, U. Perez-Salas, D. L. Worcester and S. H. White, *Rev. Sci. Instrum.*, 2006, **77**(7), 74301.
- 41 B. J. Kirby, P. A. Kienzie, B. B. Maranville, N. F. Berk, J. Krycka, F. Heinrich and C. F. Majkrzak, *Curr. Opin. Colloid Interface Sci.*, 2012, **17**, 44–53.
- 42 A. Benedetto, F. Heinrich, M. A. Gonzalez, G. Fragneto, E. Watkins and P. Ballone, *J. Phys. Chem. B*, 2014, **118**, 12192–12206.
- 43 F. Heinrich and M. Lösche, *Biochim. Biophys. Acta, Biomembr.*, 2014, **1838**, 2341–2349.
- 44 P. Shekhar, H. Nanda, M. Lösche and F. Heinrich, *J. Appl. Phys.*, 2011, **110**(10), 102216.
- 45 B. J. Kirby, P. A. Kienzie, B. B. Maranville, N. F. Berk, J. Krycka, F. Heinrich and C. F. Majkrzak, *Curr. Opin. Colloid Interface Sci.*, 2012, **17**, 44–53.
- 46 N. Kučerka, S. Tristram-Nagle and J. F. Nagle, *J. Membr. Biol.*, 2006, **208**, 193–202.
- 47 J. S. Hub, B. L. de Groot and D. van der Spoel, *J. Chem. Theory Comput.*, 2010, **6**, 3713–3720.
- 48 M. Barros, F. Heinrich, S. A. K. Datta, A. Rein, I. Karageorgos, H. Nanda, M. Lösche and W. I. Sundquist, *J. Virol.*, 2016, **90**, 4544–4555.

